Oncotelic Therapeutics Reports Improved Net Loss of $1.1 Million for Q3 2025

Oncotelic Therapeutics, Inc. reported a net loss of approximately $1.1 million for the three months ended September 30, 2025, a significant improvement compared to a net loss of about $3.4 million for the same period in 2024. The reduction in loss was primarily attributed to the absence of goodwill impairment, which had amounted to $3.2 million in the prior year. Total operating expenses for the recent quarter were approximately $491,000, down from $3.3 million in the previous year, reflecting a decrease in general and administrative expenses, which rose to $490,547 from $80,277, largely due to increased stock-based compensation and operational costs.

For the nine months ended September 30, 2025, Oncotelic reported a net loss of approximately $1.3 million, compared to a net loss of $4.1 million for the same period in 2024. The decrease in loss was again primarily due to the lack of goodwill impairment charges, which had negatively impacted the previous year's results. Operating expenses for the nine-month period totaled approximately $658,000, significantly lower than the $3.5 million reported in 2024. Research and development expenses remained relatively stable, while general and administrative expenses increased due to higher operational costs and stock-based compensation.

As of September 30, 2025, Oncotelic's total assets were approximately $28.2 million, an increase from $26.7 million at the end of 2024. The company's cash and restricted cash rose to $429,000 from $106,000, while current liabilities increased to $20.1 million from $19.2 million. The company continues to face challenges with a negative working capital of approximately $18.5 million and an accumulated deficit of about $39.1 million since inception. The company has indicated that it will need to raise additional capital to support ongoing operations and product development.

Strategically, Oncotelic has been focusing on its joint venture with GMP Bio, which is advancing the development of OT-101, a therapeutic candidate for various oncology indications. The joint venture has initiated Phase 2 and 3 clinical trials for OT-101 and is also exploring a nanoparticle platform for drug delivery. The company has entered into several financing agreements, including a recent equity purchase agreement with Mast Hill Fund, which could provide up to $25 million in funding, contingent upon the effectiveness of a registration statement with the SEC.

Looking ahead, Oncotelic's management has expressed optimism about the potential for significant value creation through its joint venture and ongoing product development. However, the company acknowledges the need for additional funding to continue its operations and meet its strategic goals. The outlook remains cautious, with management emphasizing the importance of securing capital to support clinical trials and other initiatives while navigating the challenges of the biotechnology market.